Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Published Online
on April 14, 2003

Circulation. 2003
Published online before print April 14, 2003, doi: 10.1161/01.CIR.0000066319.56234.C8
A more recent version of this article appeared on May 6, 2003
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
107/17/2221    most recent
01.CIR.0000066319.56234.C8v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nademanee, K.
Right arrow Articles by Azen, S. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nademanee, K.
Right arrow Articles by Azen, S. P.
Related Collections
Right arrow Electrophysiology
Right arrow Ablation/ICD/surgery

Submitted on November 6, 2002
Revised on February 12, 2003
Accepted on February 18, 2003

Defibrillator Versus {beta}-Blockers for Unexplained Death in Thailand (DEBUT). A Randomized Clinical Trial

Koonlawee Nademanee MD*, Gumpanart Veerakul MD, Morton Mower MD, Khanchit Likittanasombat MD, Rungroj Krittayapong MD, Kiertijai Bhuripanyo MD, Surapun Sitthisook MD, Lertlak Chaothawee MD, Mei Ying Lai MS, and Stanley P. Azen PhD

From the Pacific Rim Electrophysiology Research Institute, Los Angeles, Calif (K.N.); the Royal Thai Air Force Medical Center, Bangkok, Thailand (G.V., L.C.); Johns Hopkins University School of Medicine, Baltimore, Md (M.M.); Mahidol University, Bangkok, Thailand (K.L., R.K., K.B.); Chulalongkorn University, Bangkok, Thailand (S.S.); and the Statistical Consultation and Research Center, University of Southern California School of Medicine, Los Angeles, Calif (M.Y.L., S.P.A.).

* To whom correspondence should be addressed. E-mail: wee{at}pacificrimep.com.

Background--Sudden Unexplained Death Syndrome (SUDS) is the leading cause of death in young, healthy, Southeast Asian men. The role of an implantable cardioverter defibrillator (ICD) for mortality reduction in these patients remains unclear.

Methods and Results--The Defibrillator Versus {beta}-Blockers for Unexplained Death in Thailand (DEBUT) study is a randomized, clinical trial conducted in 2 phases (pilot study followed by the main trial) to compare the annual all-cause mortality rates among SUDS patients treated with {beta}-blockers versus that among those treated with an ICD. A total of 86 patients who were SUDS survivors and probable SUDS survivors were randomized to receive an ICD or propranolol (20 patients were in the pilot study and 66 were in the main trial). The primary end point was death from all causes. The secondary end point was recurrent ventricular tachycardia/ventricular fibrillation (VF) or cardiac arrest. During the 3-year follow-up period of the main trial, there were 4 deaths; all occurred in the {beta}-blocker group (P=0.02). Seven subjects in the ICD arm had recurrent VF, and all were effectively treated by the ICD. On the basis of the main trial results, the Data Safety Monitoring Board stopped the study. In total (both from the Pilot study and the main trial), there were 7 deaths (18%) in the {beta}-blocker group and no deaths in the ICD group, but there were a total of 12 ICD patients receiving ICD discharges due to recurrent VF.

Conclusions--ICD treatment provides full protection from death related to primary VF in a SUDS population and is superior to {beta}-blockade treatment.


Key words: fibrillation • defibrillators, implantable • death, sudden • propranolol




This article has been cited by other articles:


Home page
Circ Arrhythm ElectrophysiolHome page
R. L. Verrier and M. E. Josephson
Impact of Sleep on Arrhythmogenesis
Circ Arrhythm Electrophysiol, August 1, 2009; 2(4): 450 - 459.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P.-S. Chen and S. G. Priori
The Brugada Syndrome
J. Am. Coll. Cardiol., March 25, 2008; 51(12): 1176 - 1180.
[Full Text] [PDF]


Home page
ANN INTERN MEDHome page
J. A. Ezekowitz, B. H. Rowe, D. M. Dryden, N. Hooton, B. Vandermeer, C. Spooner, and F. A. McAlister
Systematic Review: Implantable Cardioverter Defibrillators for Adults with Left Ventricular Systolic Dysfunction
Ann Intern Med, August 21, 2007; 147(4): 251 - 262.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
F. Sacher, V. Probst, Y. Iesaka, P. Jacon, J. Laborderie, F. Mizon-Gerard, P. Mabo, S. Reuter, D. Lamaison, Y. Takahashi, et al.
Outcome After Implantation of a Cardioverter-Defibrillator in Patients With Brugada Syndrome: A Multicenter Study
Circulation, November 28, 2006; 114(22): 2317 - 2324.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
K.-H. Kuck and S. Nisam
ICD therapy: 'the sickest benefit the most...': what about the less sick?
Europace, July 1, 2006; 8(7): 508 - 511.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
S. Nisam and G. Breithardt
Lessons learned from neutral ICD trials
Europace, June 1, 2006; 8(6): 393 - 397.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
Z. Goldberger and R. Lampert
Implantable Cardioverter-Defibrillators: Expanding Indications and Technologies
JAMA, February 15, 2006; 295(7): 809 - 818.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
Additional Information
JAMA, November 2, 2005; 294(17): E1 - E3.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. P. Singh, W. J. Hall, S. McNitt, H. Wang, J. P. Daubert, W. Zareba, J. N. Ruskin, A. J. Moss, and and the MADIT-II Investigators
Factors Influencing Appropriate Firing of the Implanted Defibrillator for Ventricular Tachycardia/Fibrillation: Findings From the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II)
J. Am. Coll. Cardiol., November 1, 2005; 46(9): 1712 - 1720.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. Kadish and M. Mehra
Heart Failure Devices: Implantable Cardioverter-Defibrillators and Biventricular Pacing Therapy
Circulation, June 21, 2005; 111(24): 3327 - 3335.
[Full Text] [PDF]


Home page
CirculationHome page
B. Belhassen, A. Glick, and S. Viskin
Efficacy of Quinidine in High-Risk Patients With Brugada Syndrome
Circulation, September 28, 2004; 110(13): 1731 - 1737.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J.-S. Hermida, I. Denjoy, J. Clerc, F. Extramiana, G. Jarry, P. Milliez, P. Guicheney, S. Di Fusco, J.-L. Rey, B. Cauchemez, et al.
Hydroquinidine therapy in Brugada syndrome
J. Am. Coll. Cardiol., May 19, 2004; 43(10): 1853 - 1860.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
D. P. Zipes
The year in electrophysiology
J. Am. Coll. Cardiol., April 7, 2004; 43(7): 1306 - 1314.
[Full Text] [PDF]


Home page
Eur Heart JHome page
R. Krittayaphong, G. Veerakul, K. Nademanee, and C. Kangkagate
Heart rate variability in patients with Brugada syndrome in Thailand
Eur. Heart J., October 1, 2003; 24(19): 1771 - 1778.
[Abstract] [Full Text] [PDF]